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Abstract
Seventy-ﬁve clinical isolates of Clostridium difﬁcile from Shanghai
and 80 from Stockholm were investigated. The prevalence of
toxin A-negative, toxin B-positive isolates of C. difﬁcile among iso-
lates from Shanghai (33.3%) was signiﬁcantly higher than among
isolates from Stockholm (0%). Both sets of isolates were fully sus-
ceptible to metronidazole and vancomycin. However, the MICs of
ﬂuoroquinolones, erythromycin–clindamycin, tetracycline, rifam-
pin and fusidic acid were signiﬁcantly higher for the Shanghai iso-
lates than for the Stockholm isolates. Thirty-three PCR ribotypes
were identiﬁed; a dominant clone, 017, accounted for 18.7% of
Shanghai isolates, whereas clone 005 dominated among Stockholm
isolates, accounting for 11.3%. Strains 027 and 078 were not
detected. No outbreak occurred during the study period.
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Clostridium difﬁcile infection (CDI) is the leading cause of nos-
ocomial diarrhoea, and the number of outbreaks has risen
markedly since 2003. These outbreaks are thought to be
due, in part, to the emergence of C. difﬁcile strain 027.
Another new hypervirulent strain, 078, whose incidence
increased from 3% to 13% during 2005–2008 in The Nether-
lands, has been described [1,2].
The rates of hospital-acquired CDI in 2008 were 17.1 (78/
45 743) and 19.5 (98/55 512) per 10 000 admissions in Fu-
dan University Hospital Huashan, Shanghai China and Karo-
linska University Hospital, Stockholm, Sweden, respectively.
The aim of the present study was to compare the pheno-
typic and genotypic features of C. difﬁcile isolates from the
two hospitals.
Seventy-ﬁve non-repeated toxigenic isolates of C. difﬁcile
from Shanghai and 80 from Stockholm were studied. All were
from hospitalized age-matched and ward-matched patients,
and were conﬁrmed by biochemical tests and PCR for gluD
[3]. The non-repeating regions and repeating regions of tcdA
were detected by conventional PCR [4]. Multiplex real-time
PCR to detect tcdB, cdtA and cdtB and tcdC with a nucleotide
deletion at position 117 was performed with the GeneXpert
Dx System (Cepheid, Sunny Vale, CA, USA) according to
Huang et al. (19th ECCMID, 2009, Abstract P788). Toxin B
was reconﬁrmed with the cytotoxicity neutralization assay.
The isolates were typed by PCR ribotyping, using the method
described by Stubbs et al. [5]. In situations in which the ribo-
type was known to be a recognized international ribotype
from the PHLS Anaerobic Reference Unit (Cardiff, UK), the
appropriate numerical designation was used. Other unknown
ribotypes were serially named by using a letter designation.
The MICs of 12 antimicrobial agents were determined by
the agar dilution method, as recommended by the CLSI [6,7].
A variety of primer pairs for the ampliﬁcation of speciﬁc
sequences of ermB, tetM, gyrA and gyrB were used [8–10].
Amplicons were sequenced commercially (Euroﬁns MWG
Operon, Ebersberg, Germany).
Data were analysed with SPSS 13.0. The chi-square test
or Fisher’s exact test was applied to compare categorical
variables. The level of statistical signiﬁcance was deﬁned as
p <0.05.
Among the 75 Shanghai isolates, 25 were A)B+CDT)
(Binary Toxin), 49 were A+B+CDT), and one was
A+B+CDT+. Among the 80 Stockholm isolates, 73 were
A+B+CDT), and seven were A+B+CDT+. The prevalence of
toxin A)B+ isolates of C. difﬁcile among isolates from Shang-
hai was signiﬁcantly higher than among isolates from Stock-
holm (p <0.001). Thirty-three PCR ribotypes were identiﬁed;
a dominant clone, 017, accounted for 18.7% of Shanghai
isolates, whereas clone 005 dominated among Stockholm
isolates, accounting for 11.3% (Table 1). PCR ribotypes 027
and 078 were not detected.
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All isolates were fully susceptible to metronidazole and
vancomycin. The rates of resistance to moxiﬂoxacin, levo-
ﬂoxacin, erythromycin, clindamycin, tetracycline, rifampin and
fusidic acid were much higher in isolates from Shanghai than
in those from Stockholm (Table 2). High-level resistance to
moxiﬂoxacin (MIC ‡32 mg/L), erythromycin (MIC >128 mg/
L) and clindamycin (MIC >128 mg/L) was found in 20%,
65.3%, and 66.7%, respectively, of Shanghai isolates, as com-
pared with 1.3%, 5%, and 15%, respectively, of Stockholm
isolates (p <0.001). The rates of multiresistance to moxiﬂox-
acin, erythromycin, tetracycline and clindamycin were signiﬁ-
cantly higher for the A)B+ isolates than for the A+B+ isolates
(p <0.05).
Antimicrobial resistance genes were only investigated in
the multiresistant isolates. Among 24 multiresistant isolates
from Shanghai, 21 were ermB-positive, 24 were tetM-positive,
15 had a gyrA mutation (Thr82 ﬁ Ile, 14; Thr82 ﬁ Val,
one), two had a gyrB mutation (Asp426 ﬁ Val), and seven
had mutations in both gyrA and gyrB. All three multiresistant
Stockholm isolates were ermB-positive and tetM-positive and
had a mutation in gyrA (Thr82 ﬁ Ile).
Kato et al. [11] and Bendle et al. [12] have analysed C. difﬁ-
cile isolates from geographically distinct populations within
the same country; different types and different antibiotic sus-
ceptibilities were found, respectively. In the present study,
signiﬁcant differences were found in antimicrobial resistance,
toxin proﬁles and PCR ribotype patterns between the C. difﬁ-
cile strains from Shanghai and Stockholm.
Although A+B+ strains play a major role in CDI, A)B+
strains have been found with increasing frequency in some
parts of the world. The prevalence rates of A)B+ strains
were reported to range from 5.4% to 39.0% in different
studies from Europe and Asia [13,14]. In the present study,
33% of Shanghai isolates were A)B+, but none of the Stock-
holm isolates. As toxin B, but not toxin A, has been proven
to be the key virulence determinant [15], the diagnostic
emphasis should be on the detection of both toxins by
enzyme immunoassay and/or a standard cytotoxin assay that
measures primarily toxin B.
Although strains 027 and 078 have spread worldwide,
reports from China and Sweden are still limited. In the
present study, neither strain 027 nor strain 078 was
TABLE 1. Phenotypic and genotypic characteristics of Clostridium difﬁcile isolates from Shanghai and Stockholm
Ribotype Toxin proﬁle
Shanghai isolates (n = 75) Stockholm isolates (n = 80)
Total ADR typesa (n) Total ADR typesa (n)
002 A+B+ 0 3 II (3)
003 A+B+ 1 I (1) 1 V (1)
005 A+B+ 0 9 I (1), II (7), III (1)
012 A+B+ 13 II (1), IV (11), VII (1) 6 II (1), VII (2), IX (3)
014 A+B+ 4 I (1), II (2), V (1) 8 I (5), II (3)
015 A+B+ 0 3 I (1), II (1), VI (1)
017 A)B+ 14 I (1), VII (2), VIII (1), IX (10) 0
020 A+B+ 0 4 I (2), II (2)
023 A+B+CDT+ 1 IV (1) 7 I (6), II (1)
029 A+B+ 0 2 I (1), II (1)
046 A+B+ 5 VII (3), IX (2) 0
056 A+B+ 0 1 II (1)
106 A+B+ 0 3 I (1), II (2)
A A+B+ 13 II (1), III (1), IV (5), VII (1), VIII (5) 7 I (2), II (4), V (1)
B A+B+ 1 I (1) 0
C A+B+ 5 I (3), II (2) 2 II (2)
D A+B+ 2 VIII (2) 0
E A+B+ 1 I (1) 0
F A+B+ 2 I (1), IV (1) 0
G A)B+ 1 IX (1) 0
H A)B+ 9 IX (9) 0
I A+B+ 1 IX (1) 0
J A)B+ 1 IX (1) 0
K A+B+ 1 I (1) 6 VIII (6)
L A+B+ 0 1 I (1)
M A+B+ 0 2 II (2)
N A+B+ 0 6 I (3), II (3)
O A+B+ 0 1 I (1)
Q A+B+ 0 1 I (1)
R A+B+ 0 2 I (1), II (1)
S A+B+ 0 1 II (1)
T A+B+ 0 3 I (1), II (2)
U A+B+ 0 1 II (1)
aAntimicrobial drug resistance (ADR) proﬁles: I, no resistance; II, clindamycin resistance only; III, moxiﬂoxacin resistance only; IV, erythromycin and clindamycin resistance; V,
clindamycin and moxiﬂoxacin resistance; VI, clindamycin and tetracycline resistance; VII, erythromycin and clindamycin and tetracycline resistance; VIII, erythromycin and clin-
damycin and moxiﬂoxacin resistance; IX; erythromycin and clindamycin and moxiﬂoxacin and tetracycline resistance.
CMI Research Notes 1171
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1170–1191
found. Ribotypes 017 and 005 were most prevalent among
the isolates from Shanghai and Stockholm, respectively.
Similarly, a high prevalence of ribotype 017 has also been
found in Poland and Korea, and is often associated with
multidrug resistance [16]. Ribotype 005 is not usually
found among the major ribotypes in Europe [12,14]. How-
ever, it has been reported with a higher frequency of
resistance to clindamycin than to erythromycin, as
observed in this study.
Metronidazole and vancomycin remain the most active
agents in vitro in both sets. Recently, the emergence of
reduced susceptibility to metronidazole has been reported in
UK isolates [17]. Furthermore, Pela´ez et al. [18] reported
heteroresistance to metronidazole. In the present study,
neither reduced susceptibility nor heteroresistance was
found. The reason could be that the isolates had been frozen
before MIC tests and only the agar dilution method was
used.
The MICs of most other antimicrobial agents were higher
for the Shanghai isolates than for the Stockholm isolates.
This might be attributed, in part, to differences in selective
pressure exerted by different local antibiotic usage. Cai et al.
[19] reported that levoﬂoxacin was used as the primary pre-
scribed agent in tertiary hospitals in Shanghai during 2006.
However, further work would be needed to conﬁrm this
hypothesis.
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Abstract
A retrospective epidemiological and diagnostic study of visceral
leishmaniasis (VL) was carried out during the period 2001–2007
and included patients suspected of VL who had been diagnosed
at the Parasitological Laboratory at the Institute for Infectious
and Tropical Diseases, Belgrade. Diagnosis of VL was conﬁrmed
by microscopic examination of Giemsa-stained bone marrow
(BM) smears. BM smears from 134 patients were examined; 22
cases of VL were diagnosed, the majority of which involved indi-
viduals who had been on holiday at the Montenegrian sea coast.
The sensitivity of the initial BM smears was inadequate; this
required the application of a serological test, adapted for routine
use, for the diagnosis of VL.
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The epidemiology of leishmaniasis is extremely diverse, with
12 million people infected worldwide [1]. In the Mediterra-
nean basin, visceral leishmaniasis (VL) is caused by Leishmania
infantum, known as ‘Mediterranean kala-azar’ (MVL). The
diagnosis of MVL is complex and requires detection of
parasites in bone marrow (BM) smears [2]. Sporadic
autochthonous cases of VL have occurred in southern Serbia
(unpublished data). An epidemiological and diagnostic study
of VL was carried out at the Institute of Infectious and
Tropical Diseases in Belgrade, where most VL cases are
treated.
The study was carried out from January 2001 to Decem-
ber 2007 and included two groups (one of patients with sus-
pected VL and one control group). Informed consent was
obtained from all patients. Suspected VL was deﬁned on the
basis of a history of fever of ‡14 days with either clinical
splenomegaly or wasting syndrome. Clinical suspicion was
strengthened if the patient was from an endemic area or had
travelled to one in the recent past. Deﬁnitive diagnosis of VL
was based on direct microscopic demonstration of amastig-
otes in the BM smear. If the initial BM smear was negative
but the clinical index of suspicion was high, parasitological
investigation was repeated, or the diagnosis was based on
the clinical picture and positive serology.
All patients with suspected VL (n = 134) were examined
by performing a Giemsa-stained BM smear. BM aspirates
were obtained by sternal puncture or, if the quality of the
sternal aspirate was poor, by iliac crest biopsy. Starting in
December 2004, 26 patients were further tested using the
strip-test [3] and an indirect haemagglutination assay (IHA).
The Rapid Dipstick rK39 test (strip-test; DiaSys Europe Ltd,
Wokingham, UK) is a qualitative membrane-based immunoas-
say using the recombinant antigen K39, which is part of the
L. chagasi kinesin-related protein and is speciﬁc for all mem-
bers of the L. donovani complex [4]. In the IHA (Behring
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